PLUS THERAPEUTICS INC
PSTVNASDAQ🏆 #3497 by market capUS Equity
$94.52▲ $0.63 (+0.67%)
Simulated price1h—
24h▲ 0.7%
7d—
14d—
30d—
1y—
🏦Market Cap
$28M
Small Cap
📈Revenue Growth (YoY)
-0.5%
Declining
📊Gross Margin
74.8%
High
💵FCF Margin
18.7%
Healthy
⚖️P/S Ratio
5.4x
Fair
Otter Score
53
Weak
No chart data available for PSTV.
Trading Snapshot
- Day Range
- $93.39 – $96.06
- 52-Week Range
- $2.90 – $23.43
- Volume
- $1.94B
- Avg Volume
- $2.57B
- Shares Outstanding
- 6.9M
- Next Earnings
- Sep 23, 2026
Fundamentals Snapshot
- Annual Revenue
- $5M
- Last Q Revenue
- $1M
- P/E Ratio
- —
- P/S Ratio
- 5.4x
- EPS (TTM)
- $-2.50
- Dividend Yield
- —
Why Investors Own PSTV
- ✓High-growth profile — revenue up +43.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 57% gross margin and 5% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$5M▲ +41.2% YoY
Gross Margin (TTM)
56.9%▲ +1.4% YoY
Operating Income (TTM)
$1M▲ +41.2% YoY
Free Cash Flow (TTM)
$269,462▲ +41.2% YoY
About PLUS THERAPEUTICS INC
A company profile for PLUS THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
53/100
Analyst Price Target
ⓘAverage Target
$111.26
▲ +17.7% Upside
High Target$135.18
Low Target$85.85
Based on 36 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
PLUS THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Barron’s·5h ago
Analysts lift PSTV price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
PLUS THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.